EligibleTrials

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Recruiting · NCT04372108 · Observational (researchers observe without assigning treatment) · Lead sponsor: Janssen Scientific Affairs, LLC

View the official record on ClinicalTrials.gov →
Crohn's diseaseUlcerative colitis

Interventions studied

Other Biologic TherapiesUstekinumab

What this trial is about

The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

2 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.